REPRIEVE Facts
REPRIEVE is evaluating if a statin medication (pitavastatin calcium) is effective to prevent heart disease among people with HIV.
REPRIEVE is the largest randomized trial to date in HIV and results from REPRIEVE will help clinical researchers and clinical care providers to develop heart disease prevention and treatment guidelines, specifically for people with HIV.
REPRIEVE leadership celebrates reaching target accrual of 7500 participants. Congratulations to the University of Southern California site team for enrolling the 7500th participant!
Number of Participants
7769
Percentage of Women
32%
Mean Age
50
Mean Years Living with HIV
13
Manuscripts Published
17
Over 7500 Participants Have Joined REPRIEVE!
Here are two of their stories.
Carlos Velez-Velazquez,
San Juan, Puerto Rico
“In addition to the importance of adherence to medications, there are associated conditions that need to be treated. REPRIEVE is studying one of these conditions. Participating in REPRIEVE gives me the opportunity to contribute to possibly achieve an adequate tool to prevent heart disease, not only for me, but for the rest of the community.”
Karina McClanahan,
Dallas, Texas, USA
“Doing something that can help me and others in the future is invaluable. Prevention is the keyword to help to improve quality of life and REPRIEVE is investing into prevent vascular sicknesses that can be fatal to many. It is an honor to be part of the REPRIEVE Study.”REPRIEVE is a global study
There are over 100 clinical sites in 12 countries around the world
Supporting Organizations
